# US 2017/0283489 A1 · Chimeric Antigen Receptor Specific for SSEA4 Antigen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283489 A1
- Document ID: US20170283489A1
- Status: Published application
- Kind: A1
- Application number: 15/504,933
- Filed: 2015-08-12
- Published: 2017-10-05
- Earliest claimed: 2014-08-19
- Assignees: Miltenyi Biotec GmbH
- Applicants: Miltenyi Biotec GmbH
- Inventors: Andreas Bosio; Olaf Hardt; Andrea Aloia
- Web page: https://patentgrep.com/patent/US20170283489A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4285: {Lipids; Lipoproteins}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/30: from tumour cells
- C12N 5/0636: {T lymphocytes}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/53: Hinge
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain specific for SSEA4, a population of engineered cells expressing said CARs, and a pharmaceutical composition comprising said genetically modified cells expressing said CARs. The pharmaceutical composition may be for use of the treatment of cancer in a subject suffering from cancer, wherein at least a subpopulation of the cancerous cells of said cancer expresses SSEA4.

## Claims

### Claim 1

A chimeric antigen receptor (CAR) comprising an antigen binding domain specific for SSEA4.

### Claim 2 (depends on 1)

The CAR according to claim 1, wherein said antigen binding domain comprises the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO:2.

### Claim 3 (depends on 1)

The CAR according to claim 1, wherein the CAR comprises a transmembrane domain and & an intracellular signaling domain, wherein the transmembrane domain comprises a sequence of the transmembrane domains of CD8 and/or CD28; and wherein the intracellular signaling domain comprises a sequence of the intracellular signaling domains of one or more of CD28, CD137 and CD3zeta.

### Claim 4 (depends on 1)

The CAR according to claim 1, wherein the CAR comprises the amino acid sequence SEQ ID NO:5 or SEQ ID NO:6.

### Claim 5 (depends on 1)

The CAR according to claim 1 for the treatment of cancer in a subject suffering from cancer, and wherein at least a subpopulation of the cancerous cells of said cancer expresses SSEA4.

### Claim 6 (depends on 5)

The CAR according to claim 5, wherein said cancer is selected from the group consisting of human breast cancer, human renal cell carcinoma (RCC) and human ovarian cancer.

### Claim 7 (depends on 1)

A population of engineered cells expressing a CAR according to claim 1.

### Claim 8 (depends on 7)

The population of engineered cells according to claim 7, wherein said engineered cells are T cells or NK cells.

### Claim 9 (depends on 7)

The isolated population of engineered cells according to claim 7 for use in immunotherapy.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising genetically modified cells expressing a CAR according to claim 1 and a pharmaceutical acceptable carrier.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10 for use of the treatment of cancer in a subject suffering from cancer, wherein at least a subpopulation of the cancerous cells of said cancer expresses SSEA4.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11 and a chemotherapeutic agent for combined use of the treatment of said cancer.

### Claim 13 (depends on 11)

The pharmaceutical composition according to claim 11, wherein said cancer is selected from the group consisting of human breast cancer, human renal cell carcinoma (RCC) and human ovarian cancer.

### Claim 14 (depends on 1)

A nucleic acid comprising a nucleotide sequence encoding the CAR according to claim 1.
